|
**Overview**: Cytomegalovirus IgG Advantage Panel**Introduction**: The Cytomegalovirus IgG Advantage Panel is a diagnostic tool designed to confirm CMV IgG status using serum samples. In India, CMV IgG seropositivity is nearly universal in adults (~90 percent), indicating past infection; avidity testing distinguishes recent from long-standing immunity, crucial in pregnancy (low avidity suggests primary infection with congenital risk). High morbidity from under-testing in antenatal care, limited avidity assays in rural areas, delayed monitoring leading to fetal defects. Per microbiology practices aligned with ICMR and FOGSI guidelines, the test employs immunoassay for IgG and avidity index over 1-2 days with high specificity, valuable for risk stratification in seropositive pregnant women. This diagnostic falls under viral screening and targets pregnant women with positive CMV IgG, addressing accurate confirmation to guide amniocentesis or counseling. With elevated morbidity due to underdiagnosis of primary infection, the test supports public health efforts by enabling precise identification and reducing congenital CMV burden. Its serum-based approach ensures reliable detection.**Other Names**: CMV IgG Pnl.**FDA Status**: FDA approved, CLIA certified for immunology/microbiology, compliant with 2025 standards.**Historical Milestone**: Avidity testing advanced; in India, key in antenatal protocols.**Purpose**: The test assesses 2 parameters including CMV IgG and avidity index to guide infection status confirmation, differentiate recent/past exposure, inform pregnancy management.**Test Parameters**: 1. CMV IgG, 2. Avidity Index.**Pretest Condition**: No fasting required; patients should be pregnant with positive CMV IgG.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on pregnancy week, prior CMV results, symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of primary CMV in pregnancy including fetal defects, benefits of avidity assessment, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or immunosuppression can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High avidity indicates past infection (low fetal risk); low avidity suggests recent, necessitating specialist input. Negative IgG may require follow-up.**Specialist Consultation**: Obstetricians or infectious disease specialists should be consulted for management.**Additional Supporting Tests**: CMV IgM, PCR for confirmation.**Test Limitations**: Avidity interpretation gestational-age dependent; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, CMV Studies India 2023. |
